Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has reiterated its Buy rating for Regenxbio (NASDAQ:RGNX) and maintained a price target of $52.
October 22, 2024 | 11:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating for Regenxbio, maintaining a price target of $52, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a maintained price target of $52 by Chardan Capital suggests a positive outlook for Regenxbio. This can lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100